Call for information/EOI for neutralising antibodies.

DHSC invites suppliers to submit an EOI on neutralising antibodies and binding site, clinical trials on efficacy, safety for preventing or treating COVID-19 infection, dose&frequency, formats/routes for administering to patients, monitoring adverse affects, efficacy against SARSCoV- 2 variants, supply availability for 2021- 2022 and future years and plans for regulatory approval in the UK, if not yet approved. **Updated information on 9th December 2021** The Therapeutics Taskforce is responsible for the end-to-end...